Results 251 to 260 of about 50,045 (313)
Some of the next articles are maybe not open access.
Hematology/Oncology Clinics of North America, 2022
Adeno-associated virus (AAV)-mediated gene transfer has successfully raised, and in some cases transiently normalized, FVIII or FIX activity levels in adults with severe hemophilia. Raising FVIII/IX levels, particularly greater than ∼15 IU/dL (mild deficiency), corresponds to a marked decrease in spontaneous and provoked bleeding, dramatic reduction in
openaire +2 more sources
Adeno-associated virus (AAV)-mediated gene transfer has successfully raised, and in some cases transiently normalized, FVIII or FIX activity levels in adults with severe hemophilia. Raising FVIII/IX levels, particularly greater than ∼15 IU/dL (mild deficiency), corresponds to a marked decrease in spontaneous and provoked bleeding, dramatic reduction in
openaire +2 more sources
Hemophilia B (Factor IX Deficiency)
Hematology/Oncology Clinics of North America, 2021The biology of factor IX deficiency leading to hemophilia B has important distinctions from factor VIII deficiency that leads to hemophilia A. In this article, the authors explore the unique biology of factor IX in hemostasis, including the importance of FIX distribution to the extravascular space and the implications on dosing of factor concentrates ...
Robert F, Sidonio, Lynn, Malec
openaire +2 more sources
Seminars in Thrombosis and Hemostasis, 2018
AbstractHemophilia B (HB) is an X-linked bleeding disorder caused by deficiency of factor IX (FIX). Patients with the severe form (FIX <1%) account approximately for 30 to 45% of persons with HB and usually suffer from recurrent joint, soft-tissue, and muscle bleeds.
Cristina, Santoro +6 more
openaire +2 more sources
AbstractHemophilia B (HB) is an X-linked bleeding disorder caused by deficiency of factor IX (FIX). Patients with the severe form (FIX <1%) account approximately for 30 to 45% of persons with HB and usually suffer from recurrent joint, soft-tissue, and muscle bleeds.
Cristina, Santoro +6 more
openaire +2 more sources
Emerging drugs for hemophilia B
Expert Opinion on Emerging Drugs, 2014Hemophilia B is a rare congenital bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). Hemophilia B patients experience mild-to-severe bleeding complications according to the degree of FIX defect. Prophylaxis, with regular infusion of FIX concentrates, is nowadays, the mainstay of hemophilia care.
Pier Mannuccio, Mannucci +1 more
openaire +2 more sources
Current Management of Hemophilia B
Hematology/Oncology Clinics of North America, 1993The management of hemorrhagic episodes in patients with hemophilia B is in transition as a result of the availability of new products for replacement therapy. Although the basic principles of therapy have not changed, the new highly purified Factor IX concentrates, AlphaNine and Mononine, represent a break-through, as they appear to be safe in terms of
H R, Roberts, M E, Eberst
openaire +2 more sources
Acta Haematologica, 2001
Hemophilia B is rare in females and only a few cases have been reported. In this report, we describe a girl with a clinically severe course of hemophilia B but with a normal 46,XX karyotype. She had no signs of Turner’s syndrome or any other dysmorphic features.
S, Shetty, K, Ghosh, D, Mohanty
openaire +2 more sources
Hemophilia B is rare in females and only a few cases have been reported. In this report, we describe a girl with a clinically severe course of hemophilia B but with a normal 46,XX karyotype. She had no signs of Turner’s syndrome or any other dysmorphic features.
S, Shetty, K, Ghosh, D, Mohanty
openaire +2 more sources